Tekla Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Tekla Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$2.63M	–	225
2020 Q4	$2.63M	Hold	20,000	–	–	0.09%	148
2020 Q3	$1.01M	Hold	20,000	–	–	0.04%	179
2020 Q2	$953K	Hold	20,000	–	–	0.04%	194
2020 Q1	$980K	Hold	20,000	–	–	0.04%	177
2019 Q4	$1.15M	Buy	+20,000	New	+$990K	0.04%	179
2019 Q1	–	Sell	-27,900	Closed	-$384K	–	204
2018 Q4	$384K	Hold	27,900	–	–	0.02%	192
2018 Q3	$278K	Buy	+27,900	New	+$459K	0.01%	204

Tekla Capital Management's EIDX Position: Q1 2021 in Review

Tekla Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 20,000 shares — an estimated $2.63M sold.

Tekla Capital Management first reported a position in EIDX in Q3 2018 and held it in 7 quarters. The position peaked at $2.63M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Tekla Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 20,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.63M.
Tekla Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Tekla Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $2.63M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.